We prospectively evaluated MRD levels in a t(17;19)‐ALL case, treated with a high risk (HR) regimen in the TCCSG L04‐16 study,18 using real‐time RT‐PCR targeting of TCF3‐HLF (Figure 1). This evidence concerns the gene TCF3 and acute lymphoblastic leukemia.